CD8A and non-small cell lung carcinoma: Ferrara et al. evaluated a “senescent immune phenotype” by measuring the percentage of CD28−CD57+KLRG-1+ cells among circulating CD8+ T lymphocytes from patients with NSCLC treated with ICIs.